INSULIN Act of 2026
Summary
The INSULIN Act of 2026 (S4189) is an early-stage bill referred to committee. It would impose an insulin out-of-pocket price cap and manufacturer rebate restructuring. The primary exposed companies are Lilly ($LLY) and Novo Nordisk ($NVO), which face 10-20% net price reductions on U.S. insulin revenue. For $LLY, this represents <2% of total revenue; for $NVO, about 3-5%. Other healthcare names like $UNH, $MRK, $PFE, $JNJ, $ABBV, $ABT have negligible direct exposure. No market-moving event today.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S4189 is early-stage — no passage imminent. Market impact is limited to monitoring.
- 2.Eli Lilly ($LLY) and Novo Nordisk ($NVO) are the primary exposed tickers; insulin is 10-15% of their revenue.
- 3.Other major healthcare names ($UNH, $PFE, $MRK, $JNJ, $ABBV, $ABT) have negligible direct exposure to insulin-specific price caps.
- 4.The insulin pricing mechanism is a regulatory price cap + rebate requirement, not direct government procurement. No new federal spending authorized.
- 5.Legislative path is long — HELP Committee markup, floor votes, House passage, possible veto. No near-term catalyst.
Market Implications
No measurable market impact today. The bill is in committee with no hearing scheduled. Drug pricing risk in insurance/pharma is well-known and already partially discounted. $LLY trades at 34x earnings, reflecting GLP-1 growth premiums far outweighing any insulin headwind. If the bill advances (e.g., HELP Committee approval), expect a 1-2% single-day dip in $LLY and $NVO. For retail investors, this is a noise-level event for now. The broader healthcare sector (, , , , , ) does not move on insulin-only legislation. The bill is not a sector-wide catalyst.
Full Analysis
What happened: On March 25, 2026, Senator Shaheen (D-NH) introduced S4189, the INSULIN Act of 2026, in the 119th Congress. The bill was read twice and referred to the Committee on Health, Education, Labor, and Pensions. This is an early-stage procedural action — the bill has not been marked up, voted on, or passed. Nineteen cosponsors support it, all Democrats (based on sponsor party). Related bill S3014 (Ensuring Timely Access to Generics Act of 2025) is also in committee, suggesting a modest legislative push on drug pricing within this Congress.
The money trail: The INSULIN Act authorizes a statutory price control mechanism — specifically, it would set a maximum out-of-pocket cost for insulin patients and require manufacturers to pay rebates to offset the cap. Authorization bills set policy, not appropriations; no specific dollar amount is authorized. Actual funding for patient subsidies, if any, would require separate appropriations. The mechanism is regulatory: the bill changes how drug prices are negotiated between manufacturers, PBMs, and insurers.
Structural winners and losers: The clearest losers are Eli Lilly ($LLY) and Novo Nordisk ($NVO) — the two dominant U.S. insulin manufacturers (along with Sanofi, which is not publicly traded in the U.S.). Combined, they control ~90% of the U.S. insulin market. A 20% net price reduction on ~$10B in insulin sales translates to $2B in manufacturer revenue at risk. However, for $LLY ($34.1B revenue, 15.4% margin), insulin is ~10-12% of sales; for $NVO (est. $38B global, ~$20B U.S.), insulin is higher but still outweighed by GLP-1 drugs. Insurers and PBMs like UnitedHealth see a mixed effect: lower claims costs offset by lost PBM spread. Other healthcare behemoths — , , , , — have minimal or zero insulin exposure. The bill does not expand coverage or create new government procurement.
Timeline: The bill is at the start of its legislative journey. It must clear the HELP Committee, pass the Senate, pass the House (no companion bill identified yet), and be signed into law. The 119th Congress runs through 2027. Drug pricing legislation has historically been challenging; the Inflation Reduction Act (2022) took 18 months. At early stage, this is a monitoring event, not a trading catalyst.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Statutory price cap and rebate restructuring for insulin products: The bill imposes a maximum out-of-pocket cost for insulin and likely requires manufacturers to pay additional rebates to insurers/PBMs to offset the cap.
Who must act
Pharmaceutical manufacturers that sell insulin in the U.S. — specifically Eli Lilly (Humalog, Basaglar, etc.), Novo Nordisk (Novolog, Levemir, etc.), and Sanofi (Lantus, Apidra, etc.).
What happens
Reduced net realized price per vial/pen of insulin in commercial and Medicare Part D markets; estimated 10-30% revenue decline on insulin portfolio depending on final rebate structure.
Stock impact
Lilly's diabetes portfolio generated ~$12.5B in 2025 (Trulicity, Mounjaro, Jardiance, insulin). Insulin alone is roughly $3-4B of that. A 15-20% net price cut on insulin translates to $450-800M annual revenue hit. However, Lilly's pipeline (retatrutide, orforglipron) and GLP-1 dominance partially offset. Overall, margin impact is <2% of total revenue.
What the bill does
Same as above - statutory insulin price cap and rebate restructuring applies to all manufacturers.
Who must act
Novo Nordisk (Novolog, Fiasp, Tresiba, Levemir).
What happens
Reduced net pricing on insulin in U.S. market; Novo Nordisk derives a higher percentage of revenue from insulin vs. Lilly (insulin ~$6-7B of $34B total U.S. pharma revenue).
Stock impact
Novo's insulin revenue is approximately $6-7B in the U.S. A 15-20% net price decline hits $900M-$1.4B. However, Novo's GLP-1 portfolio (Ozempic, Rybelsus, Wegovy) comprises ~70% of revenue, insulating the company from the full insulin-only impact.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
HELP Copays Act
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services of the Department of Health and Human Services relating to "Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model".
To amend the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to require health insurance coverage of drugs indicated for the treatment of autoimmune diseases and certain blood disorders.
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Wildlife Health Coordination and Zoonotic Disease Prevention Act of 2026
Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026
A bill to amend the Public Health Service Act to streamline the review of biosimilar biological products.
Improving Home Dialysis Act of 2026
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →